News articles about Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endo International PLC earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.9776346191533 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Endo International plc (ENDP) – Notable Insider Stake – Investor … – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Endo International plc (NASDAQ:ENDP) – What Do Moving Averages Indicate? – The Investor Guide (wallstreetnews24.com)
- Endo International plc (ENDP) is at $8.62 per share and Adamas Pharmaceuticals, Inc. (ADMS) is listed at $21.37 – Stocks Gallery (stocksgallery.com)
- States Push Ahead With Investigation Into Opioid Painkillers (advfn.com)
- Himax Technologies, Inc. (HIMX) is at $10.22 per share and Amkor Technology, Inc. (AMKR) is listed at $9.81 – Stocks Gallery (stocksgallery.com)
Shares of Endo International PLC (NASDAQ ENDP) traded down 1.59% during midday trading on Friday, hitting $8.66. 3,305,571 shares of the stock were exchanged. Endo International PLC has a 12 month low of $7.41 and a 12 month high of $23.98. The firm’s 50-day moving average is $8.73 and its 200-day moving average is $10.80. The stock’s market cap is $1.93 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.86 earnings per share. Equities research analysts predict that Endo International PLC will post $3.52 earnings per share for the current year.
Several equities research analysts recently weighed in on ENDP shares. Deutsche Bank AG reduced their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, July 7th. Mizuho reissued a “buy” rating and set a $19.00 price target on shares of Endo International PLC in a research report on Thursday, August 10th. Morgan Stanley reduced their price target on shares of Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, August 10th. Royal Bank Of Canada set a $15.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research report on Monday, June 12th. Finally, Stifel Nicolaus downgraded shares of Endo International PLC from a “buy” rating to a “hold” rating and reduced their price target for the company from $22.00 to $15.00 in a research report on Friday, June 9th. Three analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $14.33.
In other news, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paul Campanelli purchased 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were purchased at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the transaction, the chief executive officer now owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The disclosure for this purchase can be found here. Insiders bought 36,000 shares of company stock worth $279,460 in the last quarter. Company insiders own 0.50% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.